Autoinjectors Market

Global Autoinjectors Market (5th Edition): Industry Trends and Global Forecasts, till 2035: Distribution by Usability (Disposable and Reusable), Route of Administration (Intramuscular, Intravenous and Subcutaneous), Type of Molecule Delivered (Antibodies, Peptides, Proteins, Small Molecules and Others), Type of Actuation Mechanism (Manual and Automatic), Volume of Container (Less than 1 mL, 1-2 mL and More than 2 mL), End-user (Ambulatory Surgical Centres, Home Settings and Hospitals and Clinics), Target Indication (Anaphylaxis, Diabetes, Migraine, Multiple Sclerosis, Rheumatoid Arthritis, Weight Loss and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    107

  • Pages
    593

  • View Count
    36894

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Marget Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentation

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates

3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Types of Drug Delivery Systems
5.3. Drawbacks of Conventional Parenteral Delivery Systems
5.4. Emerging Trend of Self-Administration
5.4.1. Rising Burden of Chronic Diseases
5.4.2. Healthcare Cost Savings
5.4.3. Need for Immediate Treatment in Emergency Situations
5.4.4. Growth of Injectable Biologics Market
5.4.5. Addressing Key User Safety Requirements

5.5. Types of Self-Administration Devices
5.5.1. Prefilled Syringes
5.5.2. Pen-Injectors
5.5.3. Needle-Free Injectors
5.5.4. Large Volume Wearable Injectors
5.5.5. Autoinjectors

5.6. Overview of Autoinjectors
5.6.1. Components of Autoinjectors
5.6.2. Classification of Autoinjectors
5.6.2.1. Classification Based on Mechanism of Action
5.6.2.2. Classification Based on Usability
5.6.2.3. Classification Based on Type of Dose Delivered

5.6.3. Manufacturing / Packaging of Autoinjectors
5.6.4. Benefits of Autoinjectors

5.7. Regulatory Considerations
5.7.1. Medical Devices
5.7.2. Drug Device Combination Products

5.8. Future Perspectives

6. PRIMARY DRUG CONTAINERS USED IN AUTOINJECTORS
6.1. Chapter Overview
6.2. Types of Packaging
6.3. Primary Drug Containers
6.3.1. Role of Primary Drug Containers

6.3.2. Cartridges
6.3.2.1. Components of Cartridges
6.3.2.2. Types of Cartridges
6.3.2.2.1. Single Chamber Cartridge
6.3.2.2.2. Dual Chamber Cartridge

6.3.2.3. Commercially Available Cartridges

6.3.3. Syringes
6.3.3.1. Components of Syringes
6.3.3.2. Classification of Syringes
6.3.3.2.1. Classification Based on Barrel Fabrication Material
6.3.3.2.2. Classification Based on Number of Chambers in the Barrel
6.3.3.2.3. Classification Based on Type of Needle

6.3.4. Vials
6.3.4.1. Components of Vials
6.3.4.2. Commercially Available Vials

6.4. Comparison of Different Fabrication Materials

7. AUTOINJECTORS: MARKET OVERVIEW
7.1. Chapter Overview
7.2. Autoinjectors: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Usability
7.2.3. Analysis by Type of Primary Drug Container
7.2.4. Analysis by Requirement of Needle
7.2.5. Analysis by Volume of Container
7.2.6. Analysis by Type of Dose Delivered
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Type of Actuation Mechanism
7.2.9. Analysis by Type of Feedback Mechanism
7.2.10. Analysis by Availability of Connectivity Feature
7.2.11. Analysis by Target Indication
7.2.12. Analysis by Type of Molecule Delivered
7.2.13. Analysis by End-user

7.3. Autoinjector Manufacturers: Overall Market Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Type of Company
7.3.6. Most Active Players: Analysis by Number of Autoinjectors

8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology

8.4. Autoinjectors: Product Competitiveness Analysis
8.4.1. Disposable Autoinjectors
8.4.2. Reusable Autoinjectors

9. BRAND POSITIONING ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Autoinjector Manufacturers: Brand Positioning Framework
9.4.1. Brand Positioning Framework: Owen Mumford
9.4.2. Brand Positioning Framework: Ypsomed
9.4.3. Brand Positioning Framework: Elcam Medical
9.4.4. Brand Positioning Framework: SHL Medical
9.4.5. Brand Positioning Framework: Union Medico
9.4.6. Brand Positioning Framework: Antares Pharma
9.4.7. Brand Positioning Framework: PreciHealth
9.4.8. Brand Positioning Framework: Jiangsu Delfu Medical Device
9.4.9. Brand Positioning Framework: Oval Medical Technologies
9.4.10. Brand Positioning Framework: Recipharm

10. AUTOINJECTOR MANUFACTURERS: DETAILED COMPANY PROFILES
10.1. Chapter Overview
10.2. Antares Pharma
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Autoinjectors Portfolio
10.2.4 Recent Developments and Future Outlook

10.3. Elcam Medical
10.3.1. Company Overview
10.3.2. Autoinjectors Portfolio
10.3.3. Recent Developments and Future Outlook

10.4. Jiangsu Delfu Medical Device
10.4.1. Company Overview
10.4.2. Autoinjectors Portfolio
10.4.3. Recent Developments and Future Outlook

10.5. Oval Medical Technologies
10.5.1. Company Overview
10.5.2. Autoinjectors Portfolio
10.5.3. Recent Developments and Future Outlook

10.6. Owen Mumford
10.6.1. Company Overview
10.6.2. Autoinjectors Portfolio
10.6.3. Recent Developments and Future Outlook

10.7. PreciHealth
10.7.1. Company Overview
10.7.2. Autoinjectors Portfolio
10.7.3. Recent Developments and Future Outlook

10.8. Recipharm
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Autoinjectors Portfolio
10.8.4. Recent Developments and Future Outlook

10.9. SHL Medical
10.9.1. Company Overview
10.9.2. Autoinjectors Portfolio
10.9.3. Recent Developments and Future Outlook

10.10. Union Medico
10.10.1. Company Overview
10.10.2. Autoinjectors Portfolio
10.10.3. Recent Developments and Future Outlook

10.11. Ypsomed
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Autoinjectors Portfolio
10.11.4. Recent Developments and Future Outlook

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Autoinjectors: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Product
11.3.5. Analysis by Type of Partner
11.3.6. Most Active Players: Analysis by Number of Partnerships

11.3.7. Analysis by Geography
11.3.7.1. Intracontinental and Intercontinental Deals
11.3.7.2. International and Local Deals

12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Autoinjectors: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Type of Patent and Patent Publication Year
12.3.3. Analysis by Patent Application Year
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Individual Assignees: Analysis by Number of Patents

12.4. Patent Benchmarking Analysis
12.4.1. Analysis By Patent Characteristics

12.5. Patent Valuation
12.6. Leading Patents by Number of Citations

13. DRUG DEVICE COMBINATIONS: COMMERCIALIZED AUTOINJECTORS
13.1. Chapter Overview
13.2. Drug Device Combinations: Commercialized Autoinjectors
13.2.1. Analysis by Approval Year
13.2.2. Analysis by Usability
13.2.3. Analysis by Type of Primary Drug Container
13.2.4. Analysis by Requirement of Needle
13.2.5. Analysis by Volume of Container
13.2.6. Analysis by Injection Time
13.2.7. Analysis by Type of Dose Delivered
13.2.8. Analysis by Route of Administration
13.2.9. Analysis by Type of Actuation Mechanism
13.2.10. Analysis by Type of Feedback Mechanism
13.2.11. Analysis by Availability of Connectivity Feature
13.2.12. Analysis by Target Indication
13.2.13. Analysis by Severity of Indication
13.2.14. Analysis by Type of Molecule Delivered
13.2.15. Analysis by End-user
13.2.16. Analysis by Target Population

13.3. Drug Device Combinations: Commercialized Autoinjector Developers
13.3.1. Analysis by Year of Establishment
13.3.2. Analysis by Company Size
13.3.3. Analysis by Location of Headquarters
13.3.4. Analysis by Company Size and Location of Headquarters
13.3.5. Analysis by Type of Company
13.3.6. Most Active Players: Analysis by Number of Commercialized Autoinjector Combination Products

14. DRUG DEVICE COMBINATIONS: EARLY AND LATE STAGE AUTOINJECTORS
14.1. Chapter Overview
14.2. Drug Device Combinations: Early and Late Stage Autoinjectors
14.2.1. Analysis by Stage of Development
14.2.2. Analysis by Route of Administration
14.2.3. Analysis by Dose Strength
14.2.4. Analysis by Target Indication
14.2.5. Analysis by Severity of Indication
14.2.6. Analysis by Type of Molecule Delivered
14.2.7. Analysis by End-user
14.2.8. Analysis by Target Population
14.2.9. Analysis by Gender of Target Population

14.3. Drug Device Combinations: Early and Late Stage Autoinjector Developers Landscape
14.3.1. Analysis by Year of Establishment
14.3.2. Analysis by Company Size
14.3.3. Analysis by Location of Headquarters
14.3.4. Analysis by Company Size and Location of Headquarters
14.3.5. Analysis by Type of Company

15. SHORT COMPANY PROFILES: AUTOINJECTOR COMBINATION PRODUCT DEVELOPERS
15.1. Chapter Overview
15.2. Amgen
15.2.1. Company Overview
15.2.2. Autoinjector Combination Product Portfolio

15.3. ChemProtect.SK
15.3.1. Company Overview
15.3.2. Autoinjector Combination Product Portfolio

15.4. Eli Lilly and Company
15.4.1. Company Overview
15.4.2. Autoinjector Combination Product Portfolio

15.5. Kindeva Drug Delivery
15.5.1. Company Overview
15.5.2. Autoinjector Combination Product Portfolio

15.6. Merck
15.6.1. Company Overview
15.6.2. Autoinjector Combination Product Portfolio

15.7. Novartis
15.7.1. Company Overview
15.7.2. Autoinjector Combination Product Portfolio

15.8. Novo Nordisk
15.8.1. Company Overview
15.8.2. Autoinjector Combination Product Portfolio

15.9. Sanofi
15.9.1. Company Overview
15.9.2. Autoinjector Combination Product Portfolio

15.10. Teva Pharmaceutical Industries
15.10.1. Company Overview
15.10.2. Autoinjector Combination Product Portfolio

16. KEY OPINION LEADER ANALYSIS
16.1. Chapter Overview
16.2. Assumption and Key Parameters
16.3. Methodology
16.4. Autoinjectors: Key Opinion Leaders
16.4.1. Analysis by Role of KOL
16.4.2. Analysis by Type of Sponsor Organization
16.4.3. Analysis by Affiliated Organization
16.4.4. Analysis by Target Indication
16.4.5. Analysis by Location of Clinical Trials
16.4.6 Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
16.4.7. Most Prominent KOLs: Analysis by Roots Analysis Score

17. CASE STUDY: KEY THERAPEUTIC INDICATIONS
17.1. Chapter Overview
17.2. Anaphylaxis
17.2.1. Overview and Epidemiology
17.2.2. Treatment for Anaphylaxis
17.2.3. Autoinjectors for Anaphylaxis

17.3. Multiple Sclerosis
17.3.1. Overview and Epidemiology
17.3.2. Treatment for Multiple Sclerosis
17.3.3. Autoinjectors for Multiple Sclerosis

17.4. Migraine
17.4.1. Overview and Epidemiology
17.4.2. Treatment for Migraine
17.4.3. Autoinjectors for Migraine

17.5. Rheumatoid Arthritis
17.5.1. Overview and Epidemiology
17.5.2. Treatment for Rheumatoid Arthritis
17.5.3. Autoinjectors for Rheumatoid Arthritis

18. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
18.1. Chapter Overview
18.2. Challenges Associated with Medical Device Manufacturing
18.3. Role of CMOs in Medical Device Manufacturing
18.4. Services Offered by Medical Device CMOs
18.5. Advantages Offered by Medical Device CMOs
18.6. Risks Associated with Outsourcing to CMOs

18.7. Drug Delivery Device Service Providers
18.7.1. Analysis by Year of Establishment
18.7.2. Analysis by Company Size
18.7.3. Analysis by Location of Headquarters
18.7.4. Analysis by Type of Services

18.8. Concluding Remarks

19. CASE STUDY: PREFILLED SYRINGES
19.1. Chapter Overview
19.2. Prefilled Syringes: Market Landscape
19.2.1. Analysis by Type of Barrel Fabrication Material
19.2.2. Analysis by Number of Barrel Chambers
19.2.3. Analysis by Type of Needle System

19.3. Prefilled Syringes Manufacturers: Overall Market Landscape
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters

19.4. Future Perspectives

20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.2.1. Ease of Drug Delivery
20.2.2. Ability to Minimize / Eliminate Medication Errors
20.2.3. Enhanced Safety Features
20.2.4. Economic Advantages
20.2.5. Drug Life Cycle Management

20.3. Weaknesses
20.3.1. Manufacturing Complexities
20.3.2. Customized Design for Different Formulations
20.3.3. Use Errors
20.3.4. Stringent Regulatory Guidelines

20.4. Opportunities
20.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
20.4.2. Growing Preference for Self-Injection Devices
20.4.3. Integration of Advanced Technologies
20.4.4. Rising Popularity across the Globe

20.5. Threats
20.5.1. Material Compatibility Issues
20.5.2. Availability of Alternative Drug Delivery Devices
20.5.3. Concern Related to Numerous Product Recalls In Past

20.6. Concluding Remarks

21. GLOBAL AUTOINJECTORS MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global Autoinjectors Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2 Optimistic Scenario

21.4. Key Market Segmentations

22. AUTOINJECTORS MARKET, BY USABILITY
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Autoinjectors Market: Distribution by Usability, 2018, 2024 and 2035
22.3.1. Disposable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2. Reusable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

22.4. Data Triangulation and Validation

23. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Autoinjectors Market: Distribution by Route of Administration, 2018, 2024 and 2035
23.3.1. Autoinjectors Market for Subcutaneous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.2. Autoinjectors Market for Subcutaneous / Intramuscular Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.3. Autoinjectors Market for Subcutaneous / Intravenous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.4. Autoinjectors Market for Intramuscular Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.5. Autoinjectors Market for Intravenous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

23.4. Data Triangulation and Validation

24. AUTOINJECTORS MARKET, BY TYPE OF MOLECULE DELIVERED
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Autoinjectors Market: Distribution by Type of Molecule Delivered, 2018, 2024 and 2035
24.3.1. Autoinjectors Market for Proteins: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.2. Autoinjectors Market for Small Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.3. Autoinjectors Market for Antibodies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.4. Autoinjectors Market for Peptides: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.5. Autoinjectors Market for Other Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

24.4. Data Triangulation and Validation

25. AUTOINJECTORS MARKET, BY TYPE OF ACTUTATION MECHANISM
25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Autoinjectors Market: Distribution by Type of Actuation Mechanism, 2018, 2024 and 2035
25.3.1. Autoinjectors Market for Automatic Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
25.3.2. Autoinjectors Market for Manual Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

26. AUTOINJECTORS MARKET, BY VOLUME OF CONTAINER
26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Autoinjectors Market: Distribution by Volume of Container, 2018, 2024 and 2035
26.3.1. Autoinjectors Market for Less than 1 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
26.3.2. Autoinjectors Market for 1- 2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
26.3.3. Autoinjectors Market for More than 2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

27. AUTOINJECTORS, BY END-USER
27.1. Chapter Overview
27.2. Assumptions and Methodology
27.3. Autoinjectors Market: Distribution by End-user, 2018, 2024 and 2035
27.3.1. Autoinjectors Market for Home Settings: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27.3.2. Autoinjectors Market for Hospitals and Clinics: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27.3.3. Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

27.4. Data Triangulation and Validation

28. AUTOINJECTORS MARKET, BY TARGET INDICATION
28.1. Chapter Overview
28.2. Assumptions and Methodology
28.3. Autoinjectors Market: Distribution by Target Indication, 2018, 2024 and 2035
28.3.1. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.2. Autoinjectors Market for Multiple Sclerosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.3 Autoinjectors Market for Diabetes: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) Data Triangulation
28.3.4. Autoinjectors Market for Anaphylaxis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.5. Autoinjectors Market for Weight Loss: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.6. Autoinjectors Market for Migraine: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.7. Autoinjectors Market for Other Indications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

28.4. Data Triangulation and Validation

29. AUTOINJECTORS, BY KEY GEOGRAPHICAL REGION
29.1. Chapter Overview
29.2. Assumptions and Methodology
29.3. Autoinjectors Market: Distribution by Key Geographical Region, 2018, 2024 and 2035
29.3.1. Autoinjectors Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.2. Autoinjectors Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.3. Autoinjectors Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.4. Autoinjectors Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.4. Autoinjectors Market in Latin America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

29.4. Data Triangulation and Validation

30. AUTOINJECTORS MARKET, FOR RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Usability
30.3.1. Disposable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.3.2. Reusable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

30.4. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Route of Administration
30.4.1. Subcutaneous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.4.2. Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.4.3. Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

30.5. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Type of Molecule Delivered
30.5.1. Proteins Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.5.2. Antibodies Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.5.3. Small Molecules Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

31. AUTOINJECTORS MARKET, FOR MULTIPLE SCLEROSIS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Autoinjectors Market for Multiple Sclerosis: Distribution by Usability
31.3.1. Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.3.2. Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

31.4. Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration
31.4.1. Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.4.2. Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

31.5. Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule Delivered
31.5.1. Proteins Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.5.2. Peptides Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.5.3. Antibodies Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

32. AUTOINJECTORS MARKET, FOR DIABETES
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Autoinjectors Market for Diabetes: Distribution by Usability
32.3.1. Disposable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.3.2. Reusable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

32.4. Autoinjectors Market for Diabetes: Distribution by Route of Administration
32.4.1. Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

32.5. Autoinjectors Market for Diabetes: Distribution by Type of Molecule Delivered
32.5.1. Proteins Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.5.2. Antibodies Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

33. AUTOINJECTORS MARKET, FOR ANAPHYLAXIS
33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Autoinjectors Market for Anaphylaxis: Distribution by Usability
33.3.1. Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

33.4. Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration
33.4.1. Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
33.4.2. Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

33.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
33.5.1. Small Molecules Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

34. AUTOINJECTORS MARKET, FOR WEIGHT LOSS
34.1. Chapter Overview
34.2. Key Assumptions and Methodology
34.3. Autoinjectors Market for Weight Loss: Distribution by Usability
34.3.1. Disposable Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

34.4. Autoinjectors Market for Weight Loss: Distribution by Route of Administration
34.4.1. Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

34.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
34.5.1. Peptides Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
34.5.2. Small Molecules Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

35. AUTOINJECTORS MARKET, FOR MIGRAINE
35.1. Chapter Overview
35.2. Key Assumptions and Methodology
35.3. Autoinjectors Market for Migraine: Distribution by Usability
35.3.1. Disposable Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

35.4. Autoinjectors Market for Migraine: Distribution by Route of Administration
35.4.1. Subcutaneous Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

35.5. Autoinjectors Market for Migraine: Distribution by Type of Molecule Delivered
35.5.1. Antibodies Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.5.2. Proteins Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.5.3. Small Molecules Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

36. AUTOINJECTORS MARKET, FOR OTHER INDICATIONS
36.1. Chapter Overview
36.2. Key Assumptions and Methodology
36.3. Autoinjectors Market for Other Indications: Distribution by Usability
36.3.1. Disposable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.3.2. Reusable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

36.4. Autoinjectors Market for Other Indications: Distribution by Route of Administration
36.4.1. Subcutaneous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.4.2. Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.4.3. Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

36.5. Autoinjectors Market for Other Indications: Distribution by Type of Molecule Delivered
36.5.1. Antibodies Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.2. Proteins Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.3. Small Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.4. Other Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)

37. CONCLUDING REMARKS

38. EXECUTIVE INSIGHTS

38.2. Aktiv Pharma
38.2.1. Company Snapshot
38.2.2. Interview Transcript

38.3. Rx Bandz
38.3.1. Company Snapshot
38.3.2. Interview Transcript

38.4. Kindeva Drug Delivery
38.4.1. Company Snapshot
38.4.2. Interview Transcript

38.5. DALI Medical Devices
38.5.1. Company Snapshot
38.5.2. Interview Transcript:

38.6. Elcam Medical
38.6.1. Company Snapshot
38.6.2. Interview Transcript

38.7. Pharma Consult
38.7.1. Company Snapshot
38.7.2. Interview Transcript

38.8. IDEO
38.8.1. Company Snapshot
38.8.2. Interview Transcript

38.9. Bill & Melinda Gates Foundation
38.9.1. Company Snapshot
38.9.2. Interview Transcript

38.10. Oval Medical Technologies
38.10.1. Company Snapshot
38.10.2. Interview Transcript

38.11. Anonymous
38.12. Anonymous
38.13. Anonymous
38.14. Anonymous

39. APPENDIX 1: TABULATED DATA

40. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Autoinjectors Market Overview
Figure 4.2 Executive Summary: Commercialized Autoinjector Combination Products Market Overview
Figure 4.3 Executive Summary: Early and Late Stage Autoinjector Combination Products Market Overview
Figure 4.4 Executive Summary: Partnerships and Collaborations
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Drug Delivery Systems
Figure 5.2 Types of Self-Injection Devices
Figure 5.3 Components of Autoinjector
Figure 5.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 5.5 Classification of Autoinjectors
Figure 7.1 Autoinjectors: Distribution by Stage of Development
Figure 7.2 Autoinjectors: Distribution by Usability
Figure 7.3 Autoinjectors: Distribution by Type of Primary Drug Container
Figure 7.4 Autoinjectors: Distribution by Requirement of Needle
Figure 7.5 Autoinjectors: Distribution by Volume of Container
Figure 7.6 Autoinjectors: Distribution by Type of Dose Delivered
Figure 7.7 Autoinjectors: Distribution by Route of Administration
Figure 7.8 Autoinjectors: Distribution by Type of Actuation Mechanism
Figure 7.9 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 7.10 Autoinjectors: Distribution by Availability of Connectivity Feature
Figure 7.11 Autoinjectors: Distribution by Target Indication
Figure 7.12 Autoinjectors: Distribution by Type of Molecule Delivered
Figure 7.13 Autoinjectors: Distribution by End-user
Figure 7.14 Autoinjector Manufacturers: Distribution by Year of Establishment
Figure 7.15 Autoinjector Manufacturers: Distribution by Company Size
Figure 7.16 Autoinjector Manufacturers: Distribution by Location of Headquarters (Region)
Figure 7.17 Autoinjector Manufacturers: Distribution by Location of Headquarters (Country)
Figure 7.18 Autoinjector Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 7.19 Autoinjector Manufacturers: Distribution by Type of Company
Figure 7.20 Most Active Players: Distribution by Number of Autoinjectors
Figure 8.1 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 8.2 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 9.1 Brand Positioning Analysis: Competitive Advantage
Figure 9.2 Brand Positioning Analysis: Reasons to Believe
Figure 9.3 Brand Positioning Matrix: Owen Mumford
Figure 9.4 Brand Positioning Matrix: Ypsomed
Figure 9.5 Brand Positioning Matrix: Elcam Medical
Figure 9.6 Brand Positioning Matrix: SHL Medical
Figure 9.7. Brand Positioning Matrix: Union Medico
Figure 9.8 Brand Positioning Matrix: Antares Pharma
Figure 9.9 Brand Positioning Matrix: PreciHealth
Figure 9.10 Brand Positioning Matrix: Jiangsu Delfu Medical Device
Figure 9.11 Brand Positioning Matrix: Oval Medical Technologies
Figure 9.12 Brand Positioning Matrix: Recipharm
Figure 10.1 Antares Pharma: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Figure 10.2 Recipharm: Annual Revenues, FY 2018-FY 2022 (SEK Billion)
Figure 10.3 Ypsomed: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2019-2024
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Figure 11.8 Partnerships and Collaborations: International and Local Deals
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2023
Figure 12.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 12.4 Patent Analysis: Distribution by Patent Application Year, Pre-2014-2023
Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 12.6 Patent Analysis: Distribution by CPC Symbols
Figure 12.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
Figure 12.8 Leading Industry Players: Distribution by Number of Patents
Figure 12.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 12 .10 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (Top CPC Codes)
Figure 12.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 12.12 Patent Analysis: Distribution by Patent Age
Figure 12.13 Patent Valuation
Figure 13.1 Commercialized Autoinjector Combination Products: Distribution by Approval Year
Figure 13.2 Commercialized AutoinjectorCombination Products: Distribution by Usability
Figure 13.3 Commercialized AutoinjectorCombination Products: Distribution by Type of Primary Drug Container
Figure 13.4 Commercialized AutoinjectorCombination Products: Distribution by Requirement of Needle
Figure 13.5 Commercialized AutoinjectorCombination Products: Distribution by Volume of Container
Figure 13.6 Commercialized AutoinjectorCombination Products: Distribution by Injection Time
Figure 13.7 Commercialized AutoinjectorCombination Products: Distribution by Type of Dose Delivered
Figure 13.8 Commercialized AutoinjectorCombination Products: Distribution by Route of Administration
Figure 13.9 Commercialized AutoinjectorCombination Products: Distribution by Type of Actuation Mechanism
Figure 13.10 Commercialized Autoinjector Combination Products: Distribution by Type of Feedback Mechanism
Figure 13.11 Commercialized Autoinjector Combination Products: Distribution by Availability of Connectivity Feature
Figure 13.12 Commercialized Autoinjector Combination Products: Distribution by Target Indication
Figure 13.13 Commercialized Autoinjector Combination Products: Distribution by Severity of Indication
Figure 13.14 Commercialized Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Figure 13.15 Commercialized Autoinjector Combination Products: Distribution by End-user
Figure 13.16 Commercialized Autoinjector Combination Products: Distribution by Target Population
Figure 13.17 Commercialized Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 13.18 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size
Figure 13.19 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Figure 13.20 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Figure 13.21 Commercialized Autoinjector Combination Product Developers: Distribution by Type of Company
Figure 13.22 Most Active Players: Distribution by Number of Commercialized Autoinjector Combination Products
Figure 14.1 Early and Late Stage Autoinjector Combination Products: Distribution by Stage of Development
Figure 14.2 Early and Late Stage Autoinjector Combination Products: Distribution by Route of Administration
Figure 14.3 Early and Late Stage Autoinjector Combination Products: Distribution by Dose Strength
Figure 14.4 Early and Late Stage Autoinjector Combination Products: Distribution by Target Indication
Figure 14.5 Early and Late Stage Autoinjector Combination Products: Distribution by Severity of Indication
Figure 14.6 Early and Late Stage Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Figure 14.7 Early and Late Stage Autoinjector Combination Products: Distribution by End-user
Figure 14.8 Early and Late Stage Autoinjector Combination Products: Distribution by Target Population
Figure 14.9 Early and Late Stage Autoinjector Combination Products: Distribution by Gender of Target Population
Figure 14.10 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 14.11 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size
Figure 14.12 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Figure 14.13 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Figure 14.14 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Type of Company
Figure 16.1 Autoinjectors KOL Analysis:Distribution by Role of KOLs
Figure 16.2 Autoinjectors KOL Analysis:Distribution by Type of Sponsor Organization
Figure 16.3 Autoinjectors KOL Analysis:Distribution by Affiliated Organization
Figure 16.4 Autoinjectors KOL Analysis:Distribution by Target Disease Indication
Figure 16.5 Autoinjectors KOL Analysis:Distribution by Location of Clinical Trials
Figure 16.6 Autoinjectors Most ProminentKOLs: Distribution by Activeness, Expertise and Strength of KOL
Figure 16.7 Autoinjectors Most ProminentKOLs: Distribution by Roots Analysis Score
Figure 18.1 Challenges Associated withMedical Device Manufacturing
Figure 18.2 Services Offered by MedicalDevice CMOs
Figure 18.3 Advantages of Outsourcing toCMOs
Figure 18.4 Risks Associated withOutsourcing to CMOs
Figure 18.5 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Year of Establishment
Figure 18.6 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Company Size
Figure 18.7 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Location of Headquarters
Figure 18.8 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Types of Services
Figure 19.1 Prefilled Syringes: Distributionby Type of Barrel Fabrication Material
Figure 19.2 Prefilled Syringes: Distributionby Number of Barrel Chambers
Figure 19.3 Prefilled Syringes: Distributionby Type of Needle System
Figure 19.4 Prefilled SyringeManufacturers: Distribution by Year of Establishment
Figure 19.5 Prefilled SyringeManufacturers: Distribution by Company Size
Figure 19.6 Prefilled SyringeManufacturers: Distribution by Location of Headquarters
Figure 20.1 Autoinjectors: SWOT Analysis
Figure 20.2 Comparison of SWOT Factors:Harvey Ball Analysis
Figure 21.1 Global Autoinjectors Market,Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 22.1 Autoinjectors Market: Distribution by Usability, 2018, 2024 and 2035
Figure 22.2 Disposable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 22.3 Reusable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 23.1 Autoinjectors Market: Distribution by Route of Administration, 2018, 2024 and 2035
Figure 23.2 Autoinjectors Market for Subcutaneous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 23.3 Autoinjectors Market for Intramuscular Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 23.4 Autoinjectors Market for Intravenous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 24.1 Autoinjectors Market: Distribution by Type of Molecule Delivered, 2018, 2024 and 2035
Figure 24.2 Autoinjectors Market for Proteins: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 24.3 Autoinjectors Market for Small Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 24.4 Autoinjectors Market for Antibodies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 24.5 Autoinjectors Market for Peptides: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 24.5 Autoinjectors Market for Other Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 25.1 Autoinjectors Market: Distribution by Type of Actuation Mechanism, 2018, 2024 and 2035
Figure 25.2 Autoinjectors Market for Automatic Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 25.3 Autoinjectors Market for Manual Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 26.1 Autoinjectors Market: Distribution by Volume of Container, 2018, 2024 and 2035
Figure 26.2 Autoinjectors Market for 1-2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 26.3 Autoinjectors Market for Less than 1 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 26.4 Autoinjectors Market for More than 2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.1 Autoinjectors Market: Distribution by Target Indication, 2018, 2024 and 2035
Figure 27.2 Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.3 Autoinjectors Market for Multiple Sclerosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.4 Autoinjectors Market for Diabetes: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) Data Triangulation
Figure 27.5 Autoinjectors Market for Anaphylaxis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.6 Autoinjectors Market for Weight Loss: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.7 Autoinjectors Market for Migraine: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 27.8 Autoinjectors Market for Other Indications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 28.1 Autoinjectors Market: Distribution by End-users, 2018, 2024 and 2035
Figure 28.2 Autoinjectors Market for Home Settings: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 28.3 Autoinjectors Market for Hospitals and Clinics: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 28.4 Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 29.1 Autoinjectors Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 29.2 Autoinjectors Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 29.3 Autoinjectors Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 29.4 Autoinjectors Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 29.5 Autoinjectors Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 29.6 Autoinjectors Market in Latin America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.1 Disposable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.2 Reusable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.3 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.4 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.5 Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.6 Proteins Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.7 Antibodies Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 30.8 Small Molecules Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.1 Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.2 Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.3 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.4 Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.5 Proteins Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.6 Peptides Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 31.7 Antibodies Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 32.1 Disposable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 32.2 Reusable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 32.3 Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 32.4 Proteins Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 32.5 Antibodies Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 33.1 Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 33.2 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 33.3 Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 33.4 Small Molecules Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 34.1 Disposable Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 34.2 Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 34.3 Peptides Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 34.4 Small Molecules Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 35.1 Disposable Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 35.2 Subcutaneous Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 35.3 Antibodies Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 35.4 Proteins Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 35.5 Small Molecules Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.1 Disposable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.2 Reusable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.3 Subcutaneous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.4 Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024 2035)
Figure 36.5 Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.5 Antibodies Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.6 Proteins Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.7 Small Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 36.8 Other Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
Figure 37.1 Concluding Remarks: Autoinjectors Market Overview
Figure 37.2 Concluding Remarks: Commercialized Autoinjector Combination Product Market Overview
Figure 37.3 Concluding Remarks: Early and Late Stage Autoinjector Combination Product Market Overview
Figure 37.4 Concluding Remarks: Partnerships andCollaborations
Figure 37.5 Concluding Remarks: Patent Analysis
Figure 37.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 5.1 Comparison of Self-Injection Devices
Table 5.2 Benefits of Autoinjectors
Table 6.1 Commercially Available Cartridges
Table 6.2 Classification of Syringes
Table 6.3 Commercially Available Glass Syringes
Table 6.4 Commercially Available Plastic Syringes
Table 6.5 Commercially Available Vials
Table 6.6 Comparison of Fabrication Material Used for Primary Drug Containers
Table 7.1 Autoinjectors: Overall Market Landscape
Table 7.2 Autoinjectors: Information on Requirement of Needle, Volume of Container, Type of Dose Delivered and Route of Administration
Table 7.3 Autoinjectors: Information on Type of Actuation Mechanism, Type of Feedback Mechanism, Availability of Connectivity Feature and Target Indication
Table 7.4 Autoinjectors: Information on Type of Molecule Delivered and End-user
Table 7.5 Autoinjector Manufacturers: Overall Market Landscape
Table 10.1 Autoinjector Manufacturers: List of Companies Profiled
Table 10.2 Antares Pharma: Company Snapshot
Table 10.3 Antares Pharma: Autoinjectors Portfolio
Table 10.4 Halozyme (Parent Company of Antares Pharma): Recent Developments and Future Outlook
Table 10.5 Elcam Medical: Company Snapshot
Table 10.6 Elcam Medical: Autoinjectors Portfolio
Table 10.7 Jiangsu Delfu Medical Device: Company Snapshot
Table 10.8 Jiangsu Delfu Medical Device: Autoinjectors Portfolio
Table 10.9 Oval Medical Technologies: Company Snapshot
Table 10.10 Oval Medical Technologies:Autoinjectors Portfolio
Table 10.11 Oval Medical Technologies:Recent Developments and Future Outlook
Table 10.12 Owen Mumford: CompanySnapshot
Table 10.13 Owen Mumford: AutoinjectorsPortfolio
Table 10.14 Owen Mumford: RecentDevelopments and Future Outlook
Table 10.15 PreciHealth: CompanySnapshot
Table 10.16 PreciHealth: AutoinjectorsPortfolio
Table 10.17 PreciHealth: RecentDevelopments and Future Outlook
Table 10.18 Recipharm: CompanySnapshot
Table 10.19 Recipharm: AutoinjectorsPortfolio
Table 10.20 Recipharm: RecentDevelopments and Future Outlook
Table 10.21 SHL Medical: CompanySnapshot
Table 10.22 SHL Medical: AutoinjectorsPortfolio
Table 10.23 SHL Medical: RecentDevelopments and Future Outlook
Table 10.24 Union Medico: CompanySnapshot
Table 10.25 Union Medico: AutoinjectorsPortfolio
Table 10.26 Ypsomed: Company Snapshot
Table 10.27 Ypsomed: AutoinjectorsPortfolio
Table 10.28 Ypsomed: RecentDevelopments and Future Outlook
Table 11.1 Autoinjectors: List of Partnerships and Collaborations, 2016-2024
Table 12.1 Patent Analysis: Top CPCSections
Table 12.2 Patent Analysis: Top CPCSymbols
Table 12.3 Patent Analysis: Top CPCCodes
Table 12.4 Patent Analysis: Summary ofBenchmarking Analysis
Table 12.5 Patent Analysis: Categorizationbased on Weighted Valuation Scores
Table 12.6 Patent Portfolio: List of LeadingPatents (by Highest Relative Valuation)
Table 12.7 Patent Portfolio: List of LeadingPatents (by Number of Citations)
Table 13.1 Drug Device Combinations: Commercialized Autoinjectors
Table 13.2 Commercialized Autoinjector Combination Products: Information on Requirement of Needle, Volume of Container, Injection Time and Type of Dose Delivered
Table 13.3 Commercialized Autoinjector Combination Products: Information on Route of Administration, Type of Actuation Mechanism, Type of Feedback Mechanism and Availability of Connectivity
Table 13.4 Commercialized Autoinjector Combination Products: Information on Target Therapeutic Indication and Severity Of Indication
Table 13.5 Commercialized Autoinjector Combination Products: Information on Type of Molecule Delivered, End-user and Target Population
Table 13.6 Commercialized Autoinjector Combination Products: List of Developers
Table 14.1 Drug Device Combinations:Early and Late Stage Autoinjectors
Table 14.2 Early and Late StageAutoinjector Combination Products: Information on Dose Strength, Target Indication and Severity of Indication
Table 14.3 Early and Late StageAutoinjector Combination Products: Information on Type of Molecule Delivered and End-user
Table 14.4 Early and Late StageAutoinjector Combination Products: Information on Target Population and Gender of Target Population
Table 14.5 Early and Late StageAutoinjector Combination Products: List of Developers
Table 15.1 Autoinjector CombinationProducts Developers: List of Companies Profiled
Table 15.2 Amgen: Company Snapshot
Table 15.3 Amgen: AutoinjectorCombination Product Portfolio
Table 15.4 ChemProtect.SK: CompanySnapshot
Table 15.5 ChemProtect.SK: AutoinjectorCombination Product Portfolio
Table 15.6 Eli Lilly and Company:Company Snapshot
Table 15.7 Eli Lilly and Company:Autoinjector Combination Product Portfolio
Table 15.8 Kindeva Drug Delivery:Company Snapshot
Table 15.9 Kindeva Drug Delivery:Autoinjector Combination Product Portfolio
Table 15.10 Merck: Company Snapshot
Table 15.11 Merck: AutoinjectorCombination Product Portfolio
Table 15.12 Novartis: Company Snapshot
Table 15.13 Novartis: AutoinjectorCombination Product Portfolio
Table 15.14 Novo Nordisk: CompanySnapshot
Table 15.15 Novo Nordisk: AutoinjectorCombination Product Portfolio
Table 15.16 Sanofi: Company Snapshot
Table 15.17 Sanofi: AutoinjectorCombination Product Portfolio2242
Table 15.18 Teva PharmaceuticalIndustries: Company Snapshot
Table 15.19 Teva PharmaceuticalIndustries: Autoinjector Combination Product Portfolio
Table 16.1 Autoinjectors: List of KeyOpinion Leaders
Table 17.1 Anaphylaxis: CommerciallyAvailable Autoinjector Combination Products
Table 17.2 Multiple Sclerosis:Commercially Available Autoinjector Combination Products
Table 17.3 Migraine: CommerciallyAvailable Autoinjector Combination Products
Table 17.4 Rheumatoid Arthritis:Commercially Available Autoinjector Combination Products
Table 18.1 List of Medical Device CMOsOffering Services for Drug Delivery Devices
Table 18.2 Medical Device CMOs OfferingServices for Drug Delivery Devices: Information on Production Services
Table 19.1 Prefilled Syringes: List ofProducts
Table 19.2 Prefilled Syringes: List ofManufacturers
Table 39.1 Autoinjectors: Distribution by Stage of Development
Table 39.2 Autoinjectors: Distribution by Usability
Table 39.3 Autoinjectors: Distribution byType of Primary Drug Container
Table 39.4 Autoinjectors: Distribution byRequirement of Needle
Table 39.5 Autoinjectors: Distribution byVolume of Container
Table 39.6 Autoinjectors: Distribution byType of Dose Delivered
Table 39.7 Autoinjectors: Distribution byRoute of Administration
Table 39.8 Autoinjectors: Distribution byType of Actuation Mechanism
Table 39.9 Autoinjectors: Distribution byType of Feedback Mechanism
Table 39.10 Autoinjectors: Distribution byAvailability of Connectivity Feature
Table 39.11 Autoinjectors: Distribution byTarget Indication
Table 39.12 Autoinjectors: Distribution by Type of Molecule Delivered
Table 39.13 Autoinjectors: Distribution by End-user
Table 39.14 Autoinjector Manufacturers: Distribution by Year of Establishment
Table 39.15 Autoinjector Manufacturers: Distribution by Company Size
Table 39.16 Autoinjector Manufacturers: Distribution by Location of Headquarters (Region)
Table 39.17 Autoinjector Manufacturers:Distribution by Location of Headquarters (Country)
Table 39.18 Autoinjector Manufacturers:Distribution by Company Size and Location of Headquarters
Table 39.19 Autoinjector Manufacturers:Distribution by Type of Company
Table 39.20 Most Active Players:Distribution by Number of Autoinjectors
Table 39.21 Antares Pharma: AnnualRevenues, FY 2017-FY 2021 (USD Billion)
Table 39.22 Recipharm: Annual Revenues,FY 2018-FY 2022 (SEK Billion)
Table 39.23 Ypsomed: Annual Revenues,FY 2018-H1 FY 2023 (CHF Billion)
Table 39.24 Partnerships andCollaborations: Cumulative Year-wise Trend, 2019-2024
Table 39.25 Partnerships andCollaborations: Distribution by Type of Partnership
Table 39.26 Partnerships andCollaborations: Distribution by Year and Type of Partnership
Table 39.27 Partnerships andCollaborations: Distribution by Type of Product
Table 39.28 Partnerships andCollaborations: Distribution by Type of Partner
Table 39.29 Most Active Players:Distribution by Number of Partnerships
Table 39.30 Partnerships andCollaborations: Intracontinental and Intercontinental Deals
Table 39.31 Partnerships andCollaborations: International and Local Deals
Table 39.32 Patent Analysis: Distributionby Type of Patent
Table 39.33 Patent Analysis: Distributionby Patent Publication Year, 2019-2023
Table 39.34 Patent Analysis: Distributionby Type of Patent and Publication Year
Table 39.35 Patent Analysis: Distributionby Patent Application Year, Pre-2014-2023
Table 39.36 Patent Analysis: Distributionby Patent Jurisdiction
Table 39.37 Patent Analysis: CumulativeYear-wise Distribution by Type of Applicant, 2019-2023
Table 39.38 Leading Industry Players:Distribution by Number of Patents
Table 39.39 Leading Individual Assignees:Distribution by Number of Patents
Table 39.40 Patent BenchmarkingAnalysis: Distribution of Leading Industry Players by Patent Characteristics (Top CPC Codes)
Table 39.41 Patent Analysis: Distributionby Patent Age
Table 39.42 Patent Analysis: PatentValuation
Table 39.43 Commercialized AutoinjectorCombination Products: Distribution by Approval Year
Table 39.44 Commercialized AutoinjectorCombination Products: Distribution by Usability
Table 39.45 Commercialized AutoinjectorCombination Products: Distribution by Type of Primary Drug Container
Table 39.46 Commercialized AutoinjectorCombination Products: Distribution by Requirement of Needle
Table 39.47 Commercialized AutoinjectorCombination Products: Distribution by Volume of Container
Table 39.48 Commercialized AutoinjectorCombination Products: Distribution by Injection Time
Table 39.49 Commercialized AutoinjectorCombination Products: Distribution by Type of Dose Delivered
Table 39.50 Commercialized AutoinjectorCombination Products: Distribution by Route of Administration
Table 39.51 Commercialized AutoinjectorCombination Products: Distribution by Type of Actuation Mechanism
Table 39.52 Commercialized AutoinjectorCombination Products: Distribution by Type of Feedback Mechanism
Table 39.53 Commercialized AutoinjectorCombination Products: Distribution by Availability of Connectivity Feature
Table 39.54 Commercialized AutoinjectorCombination Products: Distribution by Target Indication
Table 39.55 Commercialized AutoinjectorCombination Products: Distribution by Severity of Indication
Table 39.56 Commercialized AutoinjectorCombination Products: Distribution by Type of Molecule Delivered
Table 39.57 Commercialized AutoinjectorCombination Products: Distribution by End-user
Table 39.58 Commercialized AutoinjectorCombination Products: Distribution by Target Population
Table 39.59 Commercialized AutoinjectorCombination Product Developers: Distribution by Year of Establishment
Table 39.60 Commercialized AutoinjectorCombination Product Developers: Distribution by Company Size
Table 39.61 Commercialized AutoinjectorCombination Product Developers: Distribution by Location of Headquarters (Region)
Table 39.62 Commercialized AutoinjectorCombination Product Developers: Distribution by Location of Headquarters (Country)
Table 39.63 Commercialized AutoinjectorCombination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.64 Commercialized AutoinjectorCombination Product Developers: Distribution by Type of Company
Table 39.65 Most Active Players:Distribution by Number of Commercialized Autoinjector Combination Products
Table 39.66 Early and Late StageAutoinjector Combination Products: Distribution by Stage of Development
Table 39.67 Early and Late StageAutoinjector Combination Products: Distribution by Route of Administration
Table 39.68 Early and Late StageAutoinjector Combination Products: Distribution by Dose Strength
Table 39.69 Early and Late StageAutoinjector Combination Products: Distribution by Target Indication
Table 39.70 Early and Late StageAutoinjector Combination Products: Distribution by Severity of Indication
Table 39.71 Early and Late StageAutoinjector Combination Products: Distribution by Type of Molecule Delivered
Table 39.72 Early and Late StageAutoinjector Combination Products: Distribution by End-user
Table 39.73 Early and Late StageAutoinjector Combination Products: Distribution by Target Population
Table 39.74 Early and Late StageAutoinjector Combination Products: Distribution by Gender of Target Population
Table 39.75 Early and Late StageAutoinjector Combination Product Developers: Distribution by Year of Establishment
Table 39.76 Early and Late StageAutoinjector Combination Product Developers: Distribution by Company Size
Table 39.77 Early and Late StageAutoinjector Combination Product Developers: Distribution by Location of Headquarters
Table 39.78 Early and Late StageAutoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.79 Early and Late StageAutoinjector Combination Product Developers: Distribution by Type of Company
Table 39.80 Autoinjectors KOL Analysis:Distribution by Role of KOLs
Table 39.81 Autoinjectors KOL Analysis:Distribution by Type of Sponsor Organization
Table 39.82 Autoinjectors KOL Analysis:Distribution by Affiliated Organization
Table 39.83 Autoinjectors KOL Analysis:Distribution by Target Indication
Table 39.84 Autoinjectors KOL Analysis:Distribution by Location of Clinical Trials
Table 39.85 Autoinjectors Most ProminentKOLs: Distribution by Roots Analysis Score
Table 39.86 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Year of Establishment
Table 39.87 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Company Size
Table 39.88 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Location of Headquarters
Table 39.89 Medical Device CMOsOffering Services for Drug Delivery Devices: Distribution by Types of Services
Table 39.90 Prefilled Syringes:Distribution by Type of Barrel Fabrication Material
Table 39.91 Prefilled Syringes:Distribution by Number of Barrel Chambers
Table 39.92 Prefilled Syringes:Distribution by Type of Needle System
Table 39.93 Prefilled SyringeManufacturers: Distribution by Year of Establishment
Table 39.94 Prefilled SyringeManufacturers: Distribution by Company Size
Table 39.95 Prefilled SyringeManufacturers: Distribution by Location of Headquarters
Table 39.99 Global Autoinjectors Market,Historical Trends (2018-2023) (USD Billion)
Table 39.100 Global Autoinjectors Market,Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.101 Autoinjectors Market:Distribution by Usability, 2018, 2024 and 2035 (USD Billion)
Table 39.102 Disposable AutoinjectorsMarket, Historical Trends (2018-2023) (USD Billion)
Table 39.103 Disposable AutoinjectorsMarket, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.104 Reusable AutoinjectorsMarket, Historical Trends (2018-2023) (USD Billion)
Table 39.105 Reusable AutoinjectorsMarket, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.106 Autoinjectors Market:Distribution by Route of Administration, 2018, 2024 and 2035
Table 39.107 Autoinjectors Market forSubcutaneous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.108 Autoinjectors Market forSubcutaneous Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.109 Autoinjectors Market forIntramuscular Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.110 Autoinjectors Market forIntramuscular Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.111 Autoinjectors Market forIntravenous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.112 Autoinjectors Market forIntravenous Administration t, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.113 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.114 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.115 Autoinjectors Market for Subcutaneous / Intravenous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.116 Autoinjectors Market for Subcutaneous / Intravenous Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.117 Autoinjectors Market:Distribution by Type of Molecule Delivered, 2018, 2024 and 2035
Table 39.118 Autoinjectors Market forProteins, Historical Trends (2018-2023) (USD Billion)
Table 39.119 Autoinjectors Market forProteins, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.120 Autoinjectors Market forSmall Molecules, Historical Trends (2018-2023) (USD Billion)
Table 39.121 Autoinjectors Market forSmall Molecules, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.122 Autoinjectors Market forAntibodies, Historical Trends (2018-2023) (USD Billion)
Table 39.123 Autoinjectors Market forAntibodies, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.124 Autoinjectors Market forPeptides, Historical Trends (2018-2023) (USD Billion)
Table 39.125 Autoinjectors Market forPeptides, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.126 Autoinjectors Market forOther Molecules, Historical Trends (2018-2023) (USD Billion)
Table 39.127 Autoinjectors Market forOther Molecules, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.128 Autoinjectors Market:Distribution by Type of Actuation Mechanism, 2018, 2024 and 2035 (USD Billion)
Table 39.129 Autoinjectors Market forAutomatic Actuation, Historical Trends (2018-2023) (USD Billion)
Table 39.130 Autoinjectors Market forAutomatic Actuation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.131 Autoinjectors Market forManual Actuation, Historical Trends (2018-2023) (USD Billion)
Table 39.132 Autoinjectors Market forManual Actuation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.133 Autoinjectors Market:Distribution by Volume of Container, 2018, 2024 and 2035 (USD Billion)
Table 39.134 Autoinjectors Market for1-2 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.135 Autoinjectors Market for1-2 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.136 Autoinjectors Market forLess than 1 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.137 Autoinjectors Market forLess than 1 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.138 Autoinjectors Market forMore than 2 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.139 Autoinjectors Market forMore than 2 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.140 Autoinjectors Market:Distribution by Target Therapeutic Indication, 2018, 2024 and 2035
Table 39.141 Autoinjectors Market forRheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.142 Autoinjectors Market forRheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.143 Autoinjectors Market forMultiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.144 Autoinjectors Market forMultiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.145 Autoinjectors Market forDiabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.146 Autoinjectors Market forDiabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.147 Autoinjectors Market forAnaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.148 Autoinjectors Market forAnaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.149 Autoinjectors Market forWeight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.150 Autoinjectors Market forWeight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.151 Autoinjectors Market forMigraine, Historical Trends (2018-2023) (USD Billion)
Table 39.152 Autoinjectors Market forMigraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.153 Autoinjectors Market forOther Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.154 Autoinjectors Market forOther Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.155 Autoinjectors Market forHome Settings, Historical Trends (2018-2023) (USD Billion)
Table 39.156 Autoinjectors Market forHome Settings, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.157 Autoinjectors Market forHospitals and Clinics, Historical Trends (2018-2023) (USD Billion)
Table 39.158 Autoinjectors Market forHospitals and Clinics, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.159 Autoinjectors Market forAmbulatory Surgical Centers, Historical Trends (2018-2023) (USD Billion)
Table 39.160 Autoinjectors Market forAmbulatory Surgical Centers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.161 Autoinjectors Market:Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 39.162 Autoinjectors Market forNorth America, Historical Trends (2018-2023) (USD Billion)
Table 39.163 Autoinjectors Market forNorth America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.164 Autoinjectors Market forEurope, Historical Trends (2018-2023) (USD Billion)
Table 39.165 Autoinjectors Market forEurope, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.166 Autoinjectors Market forAsia-Pacific, Historical Trends (2018-2023) (USD Billion)
Table 39.167 Autoinjectors Market forAsia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.168 Autoinjectors Market forMiddle East and North Africa, Historical Trends (2018-2023) (USD Billion)
Table 39.169 Autoinjectors Market forMiddle East and North Africa, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.170 Autoinjectors Market forLatin America, Historical Trends (2018-2023) (USD Billion)
Table 39.171 Autoinjectors Market forLatin America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.172 Disposable AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.173 Disposable AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.174 Reusable AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.175 Reusable AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.176 Subcutaneous AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.177 Subcutaneous AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.178 Subcutaneous / IntravenousAutoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.179 Subcutaneous / IntravenousAutoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.180 Intravenous AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.181 Intravenous AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.182 Proteins AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.183 Proteins AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.184 Antibodies AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.185 Antibodies AutoinjectorsMarket for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.186 Small MoleculesAutoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.187 Small MoleculesAutoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.188 Disposable AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.189 Disposable AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.190 Reusable AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.191 Reusable AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.192 Subcutaneous AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.193 Subcutaneous AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.194 Intramuscular AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.195 Intramuscular AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.196 Proteins AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.197 Proteins AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.198 Peptides AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.199 Peptides AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.200 Antibodies AutoinjectorsMarket for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.201 Antibodies AutoinjectorsMarket for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.202 Disposable AutoinjectorsMarket for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.203 Disposable AutoinjectorsMarket for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.204 Reusable AutoinjectorsMarket for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.205 Reusable AutoinjectorsMarket for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.206 Subcutaneous AutoinjectorsMarket for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.207 Subcutaneous AutoinjectorsMarket for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.208 Proteins AutoinjectorsMarket for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.209 Proteins AutoinjectorsMarket for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.210 Antibodies AutoinjectorsMarket for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.211 Antibodies AutoinjectorsMarket for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.212 Disposable AutoinjectorsMarket for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.213 Disposable AutoinjectorsMarket for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.214 Intramuscular AutoinjectorsMarket for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.215 Intramuscular AutoinjectorsMarket for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.216 Subcutaneous / IntramuscularAutoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.217 Subcutaneous / IntramuscularAutoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.218 Small MoleculesAutoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.219 Small MoleculesAutoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.220 Disposable AutoinjectorsMarket for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.221 Disposable AutoinjectorsMarket for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.222 Subcutaneous AutoinjectorsMarket for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.223 Subcutaneous AutoinjectorsMarket for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.224 Peptides AutoinjectorsMarket for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.225 Peptides AutoinjectorsMarket for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.226 Small MoleculesAutoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.227 Small MoleculesAutoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.228 Disposable AutoinjectorsMarket for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.229 Disposable AutoinjectorsMarket for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.230 Subcutaneous AutoinjectorsMarket for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.231 Subcutaneous AutoinjectorsMarket for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.232 Antibodies AutoinjectorsMarket for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.233 Antibodies AutoinjectorsMarket for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.234 Proteins AutoinjectorsMarket for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.235 Proteins AutoinjectorsMarket for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.236 Small MoleculesAutoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.237 Small MoleculesAutoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.238 Disposable AutoinjectorsMarket for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.239 Disposable AutoinjectorsMarket for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.240 Reusable AutoinjectorsMarket for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.241 Reusable AutoinjectorsMarket for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.242 Subcutaneous AutoinjectorsMarket for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.243 Subcutaneous AutoinjectorsMarket for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.244 Subcutaneous / IntramuscularAutoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.245 Subcutaneous / IntramuscularAutoinjectors Market for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.246 Subcutaneous / IntravenousAutoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.247 Subcutaneous / IntravenousAutoinjectors Market for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.248 Antibodies AutoinjectorsMarket for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.249 Antibodies AutoinjectorsMarket for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.250 Proteins AutoinjectorsMarket for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.251 Proteins AutoinjectorsMarket for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.252 Small MoleculesAutoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.253 Small MoleculesAutoinjectors Market for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.254 Other MoleculesAutoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.255 Other MoleculesAutoinjectors Market for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. AbbVie
  2. AFT Pharmaceuticals
  3. Aktiv Pharma
  4. ALK
  5. Allergy Force
  6. Allergy Therapeutics
  7. Altaviz
  8. Alvogen
  9. Alvotech
  10. Amgen
  11. Amneal Pharmaceuticals
  12. Androsystems
  13. Antares Pharma
  14. Asahi Kasei
  15. Asarina Pharma
  16. Ascendis Pharma
  17. Ashvattha Therapeutics
  18. AstraZeneca
  19. Battelle
  20. Bausch Health Companies
  21. Bayer
  22. Becton, Dickinson and Company (BD)
  23. Biocorp
  24. Biogen
  25. BioGene Pharmaceutical
  26. Biomedical Advanced Research and Development Authority 
  27. Blue Lead Medical 
  28. Boehringer Ingelheim
  29. Bregma 
  30. Brigham and Women's Hospital
  31. Bristol-Myers Squibb
  32. Canadian Medical & Surgical Knowledge Translation Research Group
  33. Celltrion 
  34. Cenexi 
  35. Center for Neurology Studies
  36. ChemProtect.SK
  37. Chugai
  38. CinnaGen
  39. Coherus BioSciences 
  40. Congruence Medical Solutions
  41. Covis Pharma 
  42. Creare
  43. Crossject
  44. CSL
  45. Danish Headache Center
  46. Difinity Solutions
  47. DIS+
  48. DMK Pharmaceuticals 
  49. Dr. Reddy's Laboratories
  50. Duoject Medical Systems
  51. Eco-inject 
  52. Eisai
  53. Elcam Medical
  54. Eli Lilly and Company
  55. Emergent BioSolutions
  56. Eton Pharmaceuticals
  57. Europlaz
  58. Ferring Pharmaceuticals 
  59. Fresenius Kabi
  60. FUJIFILM Diosynth Biotechnologies
  61. Fujifilm Kyowa Kirin Biologics
  62. Galderma
  63. Gazi University
  64. GEMABIOTECH
  65. Genentech
  66. Gerresheimer
  67. GlaxoSmithKline
  68. Halozyme
  69. Haselmeier
  70. Hospices Civils de Lyon
  71. Icahn School of Medicine at Mount Sinai
  72. Idorsia 
  73. Insel Group
  74. Ionis 
  75. Insmed
  76. Ipsen 
  77. IQVIA
  78. JT Biotech 
  79. Jabil
  80. Jiangsu Delfu 
  81. Johns Hopkins University
  82. Johnson & Johnson Innovative Medicine
  83. Johnson Medtech (a subsidiary of Johnson Electric Holdings Limited)
  84. Junshi Biosciences
  85. Kaleo
  86. Kindeva Drug Delivery
  87. Komarik
  88. Kwang Dong Pharmaceutical
  89. LCA Automation
  90. LG Chem
  91. Lifecore Biomedical
  92. Lunatus
  93. Medexus Pharmaceuticals
  94. MedsForAll
  95. Merck
  96. Meridian Medical Technologies
  97. Metis Foundation
  98. Midas Pharma
  99. MoonLake Immunotherapeutics
  100. Mylan
  101. National Institute of Allergy and Infectious Diseases
  102. Neuma
  103. Nordic Pharma
  104. Novartis 
  105. Novo Nordisk
  106. Organon
  107. Oslo University Hospital
  108. Otsuka Pharmaceutical
  109. Oval Medical Technologies
  110. Owen Mumford
  111. Palatin
  112. Parexel
  113. Pfizer
  114. Pharma Consult (PHC)
  115. Phillips Medisize
  116. Portal Instruments
  117. PPD (a part of Thermo Fisher Scientific)
  118. PRA Health Sciences
  119. PreciHealth
  120. Purdue
  121. Rafa 
  122. RAVIMED
  123. Recipharm
  124. Regeneron
  125. Resilience
  126. Rx Bandz
  127. S3 Connected Health
  128. Samsung Bioepis
  129. Sandoz
  130. Sanofi
  131. Shaily Engineering Plastics
  132. SHL Medical 
  133. Sidekick Health
  134. Solteam 
  135. STADA
  136. SteriPack
  137. Steriscience
  138. Stevanato Group
  139. Subcuject
  140. Sun Pharma
  141. Superior Tooling 
  142. Survival Technologies
  143. SwissMedDev
  144. Takeda
  145. Terumo
  146. Teva Pharmaceutical Industries
  147. Timm Medical 
  148. Tulane University
  149. U.S. Department of Defense
  150. UCB 
  151. UMC Utrecht
  152. Union Medico
  153. University of Michigan
  154. Valeo Pharma
  155. Viatris
  156. Walgreens 
  157. Wanhai Medical Instruments
  158. Weibel CDS
  159. Weiss-Aug
  160. West Pharmaceutical Services
  161. Windgap Medical 
  162. Xeris Pharmaceuticals
  163. Ypsomed
  164. Zealand Pharma
  165. Zollner

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com